ReviewNature reviews. Nephrology2014
Deferasirox nephrotoxicity-the knowns and unknowns.
Review in Nature reviews. Nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Artesunate directly targets glucosylceramidase to suppress hepatocellular carcinoma proliferation and trigger apoptosis.Genes & diseases · 2026Article
- Acute kidney injury and iron metabolism: A narrative review focusing on pathophysiology and therapy.Smart molecules : open access · 2025Review
- Elucidating the High Affinity Copper(II) Complexation by the Iron Chelator Deferasirox Provides Therapeutic and Toxicity Insight.ChemMedChem · 2025Article
- Highly sensitive AIEE active fluorescent probe for detection of deferasirox: extensive experimental and theoretical studies.RSC advances · 2024Article
- Case report: Acute liver failure during deferasirox therapy and the potential role of pharmacogenetics.Frontiers in pharmacology · 2024Article
- Nephrological Complications in Hemoglobinopathies: SITE Good Practice.Journal of clinical medicine · 2023Article
- Regulated cell death pathways in kidney disease.Nature reviews. Nephrology · 2023Review
- Mitochondria as a target of third row transition metal-based anticancer complexes.Current opinion in chemical biology · 2023Review
- Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges.Journal of blood medicine · 2023Review
- Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria.British journal of haematology · 2022Article
- Metabolic mechanisms of acute proximal tubular injury.Pflugers Archiv : European journal of physiology · 2022Review
- 2D-ultrathin MXene/DOXjade platform for iron chelation chemo-photothermal therapy.Bioactive materials · 2022Article
- A DFX-based iron nanochelator for cancer therapy.Frontiers in bioengineering and biotechnology · 2022Article
- Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review.Children (Basel, Switzerland) · 2021Review
- Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients.Pharmaceutics · 2021Article
- Assessment of Subclinical Renal Glomerular and Tubular Dysfunction in Children with Beta Thalassemia Major.Children (Basel, Switzerland) · 2021Article
- Artesunate induces ER-derived-ROS-mediated cell death by disrupting labile iron pool and iron redistribution in hepatocellular carcinoma cells.American journal of cancer research · 2021Article
- The multifaceted role of iron in renal health and disease.Nature reviews. Nephrology · 2020Review
- The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability.Scientific reports · 2020Article
- Thalassemia: Common Clinical Queries in Management.Indian journal of pediatrics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2005, the oral iron chelator deferasirox was approved by the FDA for clinical use as a first-line therapy for blood-transfusion-related iron overload. Nephrotoxicity is the most serious and frequent adverse effect of deferasirox treatment. This nephrotoxicity can present as an acute or chronic decrease in glomerular filtration rate (GFR). Features of proximal tubular dysfunction might also be present. In clinical trials and observational studies, GFR is decreased in 30-100% of patients treated with deferasirox, depending on dose, method of assessment and population studied. Nephrotoxicity is usually nonprogressive and/or reversible and rapid iron depletion is one of several risk factors. Scarce data are available on the molecular mechanisms of nephrotoxicity and the reasons for the specific proximal tubular sensitivity to the drug. Although deferasirox promotes apoptosis of cultured proximal tubular cells, the trigger has not been well characterized. Observational studies are required to track current trends in deferasirox prescription, assess the epidemiology of deferasirox nephrotoxicity in routine clinical practice, explore the effect on outcomes of various monitoring and dose-adjustment protocols and elucidate the long-term consequences of the different features of nephrotoxicity. Deferasirox nephrotoxicity can be more common in the elderly; thus, specific efforts should be dedicated to investigate the effect of deferasirox use in this group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.